Clinical Trials Directory

Trials / Conditions / Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7

Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7

11 registered clinical trials studyying Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 — 1 currently recruiting.

StatusTrialSponsorPhase
WithdrawnNivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal C
NCT03575234
Emory UniversityPhase 1
Active Not RecruitingIpilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squ
NCT03799445
M.D. Anderson Cancer CenterPhase 2
TerminatedAlpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
NCT03601507
University of ArizonaPhase 2
TerminatedACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Tr
NCT02917629
National Cancer Institute (NCI)Phase 2
CompletedDurvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell
NCT03144778
M.D. Anderson Cancer CenterPhase 1
Active Not RecruitingTesting the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Canc
NCT02567422
National Cancer Institute (NCI)Phase 1
CompletedCisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Hea
NCT02775812
National Cancer Institute (NCI)Phase 1
CompletedOnalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Recei
NCT02381535
National Cancer Institute (NCI)Phase 1
Active Not RecruitingIntensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage
NCT01893307
M.D. Anderson Cancer CenterPhase 3
CompletedIpilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreate
NCT01935921
National Cancer Institute (NCI)Phase 1
RecruitingTesting Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy
NCT01810913
National Cancer Institute (NCI)Phase 2 / Phase 3